Standard BioTools Exceeds 2025 Revenue Guidance, Anticipates $550M Cash Post-SomaLogic Sale

summarizeSummary

Standard BioTools announced preliminary 2025 revenue exceeding guidance and confirmed the SomaLogic divestiture is on track to yield $550 million in cash, significantly bolstering its financial position.

check_boxKey Events

• Preliminary 2025 Revenue Exceeds Guidance

  Standard BioTools reported preliminary, unaudited combined company revenue of approximately $185 million for the full year 2025, exceeding its previous guidance range.

• SomaLogic Divestiture on Track

  The sale of SomaLogic to Illumina is progressing as planned and is expected to close in the first half of 2026.

• Significant Cash Inflow Expected

  Upon the closing of the SomaLogic transaction, the company anticipates having approximately $550 million in cash, providing substantial strategic flexibility.

• Path to Profitability and Strategic M&A

  The company is on its way to positive adjusted EBITDA and plans to pursue disciplined mergers and acquisitions to build a diversified leader in life sciences.

auto_awesomeAnalysis

Standard BioTools Inc. reported preliminary 2025 revenue figures that surpassed its guidance range, indicating strong operational performance. The company's CEO highlighted steady execution and progress towards profitability through streamlined operations and improved cost structure. Crucially, the update confirms the SomaLogic divestiture is on track to close in the first half of 2026, which is expected to provide approximately $550 million in cash. This substantial cash infusion, exceeding the company's current market capitalization, offers significant strategic flexibility for disciplined M&A and future growth initiatives, positioning the company as a more resilient business.